CAMP4 Therapeutics Corporation
$4.24
+1.7%CAMP4 Therapeutics Corp. operates as a biotechnology company which engages in the discovery of treatment options for patients. The company was founded by Richard A. Young and Leonard Zon in 2015 and is headquartered in Cambridge, MA.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -1.6).
Valuation inputs: P/E -1.6, earnings yield N/A, momentum +1.7%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -1.7%, ROIC -50.7%).
Profitability stack: net margin -23.0%, ROE -1.7%, ROIC -50.7%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +59.5%, momentum +1.7%, net margin -23.0%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
CAMP4 Therapeutics Corporation Market vs Earnings Trajectory
Loading price and EPS data...
CAMP4 Therapeutics Corporation Fair Value Envelope
CAMP4 Therapeutics Corporation Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
CAMP4 Therapeutics Corporation Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Weak cash conversion. Significant portion of earnings not converting to cash—review working capital trends and capital intensity.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
CAMP4 Therapeutics Corporation Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
High financial leverage. Heavy reliance on debt may indicate increased financial risk and potential solvency concerns.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Mixed signals: Strong short-term liquidity provides comfort, but high overall leverage requires careful monitoring of debt servicing capabilities and refinancing risk.
CAMP4 Therapeutics Corporation Street Expectations Map
Wall Street analysts project that CAMP stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 11.40, with estimates ranging from a low of 5.00 to a high of 18.00.
The consensus 1-year price target stands at 11.40, with estimates ranging from a low of 5.00 to a high of 18.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
High uncertainty. Very wide target spread indicates significant disagreement among analysts—major valuation uncertainty or transformation underway.
Analyst Conviction
High uncertainty: Wide dispersion indicates analysts struggle to agree on valuation—proceed with caution and independent analysis.
Market Sentiment Insight
High risk, high reward: Substantial upside potential exists, but wide analyst disagreement signals execution risk or unclear catalysts. Thorough due diligence essential before committing capital.
CAMP4 Therapeutics Corporation Insider Positioning
During the last 12 months, insiders have purchased $9.43M and sold $18K worth of CAMP shares, resulting in $9.41M of net buying activity.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
6.1M
9.32M
5.0K
17.65K
+9.3M
+$9.30M
9-12 Months
72.0K
112.32K
0
0.00
+112K
+$112K
Top Buyers
Schwab Andrew J.
Director, 10 Percent Owner:
$4.51M
5Am Partners Vi, Llc
10 Percent Owner
$4.50M
Nashat Amir
Director, 10 Percent Owner:
$145K
Polaris Management Co. Vii, L.L.C.
10 Percent Owner
$131K
Young Richard A
Director
$39K
Top Sellers
Tardiff Daniel
Officer: Chief Scientific Officer
$18K
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $9.41M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.
Insider Participation
5 insider buyers vs. 1 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
No Dividend Yield Data
CAMP has not reported any dividend yield values in the available annual periods.
camp Dividend History
Learning Layer
Related Guides
Build conviction on CAMP by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.